Journal of Medicinal Chemistry · 2004 · 103 citations · 11 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular VirologyAntiviral AgentsAntiviral PharmacologyEnzyme InhibitionLigand-based DesignPeptide Drug DiscoveryPeptidomimetic DesignAcute Viral InfectionAntiviral Drug DesignAntiviral Structure-activity RelationshipsAntiviral TherapeuticsPeptide Medicinal ChemistryReversible InhibitionSevere Acute Respiratory SyndromeStructure-based Ligand Design
The 3C-like proteinase (3CL(pro)) of severe acute respiratory syndrome (SARS) coronavirus is a key target for structure-based drug design against this viral infection. The enzyme recognizes peptide substrates with a glutamine residue at the P1 site. A series of keto-glutamine analogues with a phthalhydrazido group at the alpha-position were synthesized and tested as reversible inhibitiors against SARS 3CL(pro). Attachment of tripeptide (Ac-Val-Thr-Leu) to these glutamine-based "warheads" generated significantly better inhibitors (4a-c, 8a-d) with IC(50) values ranging from 0.60 to 70 microM.
11
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Dean D. Erdman, Goldsmith Cs, Zaki et al. · New England Journal of Medicine · 2003 · 4.5K citations
Coronavirus Main Proteinase (3CL <sup>pro</sup> ) Structure: Basis for Design of Anti-SARS Drugs
K. Anand, John Ziebuhr, Parvesh Wadhwani et al. · Science · 2003 · 1.8K citations